

SEQUENCE LISTING

<110> Tomizawa, Kazuhito

Matsui, Hideki

<120> Inhibitor of constitutive active forming of carcineurin

<130> JP-13650

<160> 6

<210> 1

<211> 16

<212> PRT

<213> human

<400> 1

Phe Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys

1

5

10

15

<210> 2

<211> 17

<212> PRT

<213> human

<400> 2

Arg Glu Glu Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr

1

5

10

15

Gly

<210> 3

<211> 521

<212> PRT

<213> human

<400> 3

Met Ser Glu Pro Lys Ala Ile Asp Pro Lys Leu Ser Thr Thr Asp Arg
1 5 10 15

Val Val Lys Ala Val Pro Phe Pro Pro Ser His Arg Leu Thr Ala Lys
20 25 30

Glu Val Phe Asp Asn Asp Gly Lys Pro Arg Val Asp Ile Leu Lys Ala
35 40 45

His Leu Met Lys Glu Gly Arg Leu Glu Glu Ser Val Ala Leu Arg Ile
50 55 60

Ile Thr Glu Gly Ala Ser Ile Leu Arg Gln Glu Lys Asn Leu Leu Asp
65 70 75 80

Ile Asp Ala Pro Val Thr Val Cys Gly Asp Ile His Gly Gln Phe Phe
85 90 95

Asp Leu Met Lys Leu Phe Glu Val Gly Gly Ser Pro Ala Asn Thr Arg

100	105	110
Tyr Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Tyr Phe Ser Ile Glu		
115	120	125
Cys Val Leu Tyr Leu Trp Ala Leu Lys Ile Leu Tyr Pro Lys Thr Leu		
130	135	140
Phe Leu Leu Arg Gly Asn His Glu Cys Arg His Leu Thr Glu Tyr Phe		
145	150	155
		160
Thr Phe Lys Gln Glu Cys Lys Ile Lys Tyr Ser Glu Arg Val Tyr Asp		
165	170	175
Ala Cys Met Asp Ala Phe Asp Cys Leu Pro Leu Ala Ala Leu Met Asn		
180	185	190
Gln Gln Phe Leu Cys Val His Gly Gly Leu Ser Pro Glu Ile Asn Thr		
195	200	205
Leu Asp Asp Ile Arg Lys Leu Asp Arg Phe Lys Glu Pro Pro Ala Tyr		
210	215	220
Gly Pro Met Cys Asp Ile Leu Trp Ser Asp Pro Leu Glu Asp Phe Gly		
225	230	235
		240
Asn Glu Lys Thr Gln Glu His Phe Thr His Asn Thr Val Arg Gly Cys		
245	250	255

Ser Tyr Phe Tyr Ser Tyr Pro Ala Val Cys Asp Phe Leu Gln His Asn
 260 265 270

Asn Leu Leu Ser Ile Leu Arg Ala His Glu Ala Gln Asp Ala Gly Tyr
 275 280 285

Arg Met Tyr Arg Lys Ser Gln Thr Thr Gly Phe Pro Ser Leu Ile Thr
 290 295 300

Ile Phe Ser Ala Pro Asn Tyr Leu Asp Val Tyr Asn Asn Lys Ala Ala
 305 310 315 320

Val Leu Lys Tyr Glu Asn Asn Val Met Asn Ile Arg Gln Phe Asn Cys
 325 330 335

Ser Pro His Pro Tyr Trp Leu Pro Asn Phe Met Asp Val Phe Thr Trp
 340 345 350

Ser Leu Pro Phe Val Gly Glu Lys Val Thr Glu Met Leu Val Asn Val
 355 360 365

Leu Asn Ile Cys Ser Asp Asp Glu Leu Gly Ser Glu Glu Asp Gly Phe
 370 375 380

Asp Gly Ala Thr Ala Ala Ala Arg Lys Glu Val Ile Arg Asn Lys Ile
 385 390 395 400

Arg Ala Ile Gly Lys Met Ala Arg Val Phe Ser Val Leu Arg Glu Glu
 405 410 415

Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly Met Leu
 420 425 430

Pro Ser Gly Val Leu Ser Gly Gly Lys Gln Thr Leu Gln Ser Ala Thr
 435 440 445

Val Glu Ala Ile Glu Ala Asp Glu Ala Ile Lys Gly Phe Ser Pro Gln
 450 455 460

His Lys Ile Thr Ser Phe Glu Glu Ala Lys Gly Leu Asp Arg Ile Asn
 465 470 475 480

Glu Arg Met Pro Pro Arg Arg Asp Ala Met Pro Ser Asp Ala Asn Leu
 485 490 495

Asn Ser Ile Asn Lys Ala Leu Ala Ser Glu Thr Asn Gly Thr Asp Ser
 500 505 510

Asn Gly Ser Asn Ser Ser Asn Ile Gln
 515 520

<210> 4

<211> 11

<212> PRT

<213> HIV virus

<400> 4

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg

1 5 10

<210> 5

<211> 26

<212> PRT

<213> human

<400> 5

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Phe Asp Gly Ala Thr Ala

1 5 10 15

Ala Ala Arg Lys Glu Val Ile Arg Asn Lys

20 25

<210> 6

<211> 27

<212> PRT

<213> human

<400> 6

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Glu Glu Ser Glu Ser

1 5 10 15

Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly

20

25